Tags | Domains | Searches | Statistics | Options | Advanced Search
|
Tags | Domains | Searches | Statistics | Options | Advanced Search |
Know More Media - Health Care / Pharmaceutical / Fitness - May 23, 2008
A drug called Exforge, by pharmaceutical Novartis Ag, could help to significantly reduce high blood pressure in black patients. Using this drug reduces systolic blood pressure more than just amlodipine. Exforge is a …
Also tagged: hypertension, patents and clinical trials, exforge
PharmaGazette - May 23, 2008
A drug called Exforge, by pharmaceutical Novartis Ag, could help to significantly reduce high blood pressure in black patients. Using this drug reduces systolic blood pressure more than just amlodipine. Exforge is a …
Also tagged: hypertension, patents and clinical trials
Know More Media - Health Care / Pharmaceutical / Fitness - Jan 24, 2008
On Friday Philippines health regulators, The Bureau of Food and Drugs, ordered Novartis to "immediately initiate a product recall and cease and desist from further importing, distributing, or selling Lumiracoxib …
Also tagged: philipppines, drug recall, prexige
PharmaGazette - Jan 24, 2008
On Friday Philippines health regulators, The Bureau of Food and Drugs, ordered Novartis to "immediately initiate a product recall and cease and desist from further importing, distributing, or selling Lumiracoxib …
Also tagged: philipppines, drug recall, prexige
Know More Media - Health Care / Pharmaceutical / Fitness - Jan 22, 2008
Tekturna, a high blood pressure medication that was previously approved last March by the U.S. Food and Drug Administration, has received new approval for its combined form of hypertension medication and diuretic …
Also tagged: dri, drug regulations and approval, tekturna hypertension
PharmaGazette - Jan 22, 2008
Tekturna, a high blood pressure medication that was previously approved last March by the U.S. Food and Drug Administration, has received new approval for its combined form of hypertension medication and diuretic …
Also tagged: dri, drug regulations and approval
PharmaGazette - Dec 8, 2007
CORONA, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Novartis Pharmaceuticals …
Also tagged: r, wpi, watson, lawsuits and litigations, exelon
Know More Media - Health Care / Pharmaceutical / Fitness - Dec 8, 2007
CORONA, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Novartis Pharmaceuticals …
Also tagged: r, wpi, watson, lawsuits and litigations, exelon
PharmaGazette - Dec 6, 2007
March 2007 had the U. S Food and Drug Administration asking Novartis Pharmaceuticals to voluntarily discontinue marketing of Zelnorm (tegaserod). The request comes on the heels of the recently identified finding of …
Also tagged: fda, zelnorm, drug warnings
Know More Media - Health Care / Pharmaceutical / Fitness - Dec 5, 2007
March 2007 had the U. S Food and Drug Administration asking Novartis Pharmaceuticals to voluntarily discontinue marketing of Zelnorm (tegaserod). The request comes on the heels of the recently identified finding of …
Also tagged: fda, zelnorm, drug warnings